A Phase 1 Study of IRX195183, a RARα-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML

Subsets of non-acute promyelocytic leukemia (APL) acute myelogenous leukemia (AML) exhibit aberrant retinoid signaling and demonstrate sensitivity to retinoids in vitro. We present the results of a phase 1 dose-escalation study that evaluated the safety, pharmacodynamics, and efficacy of IRX195183,...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Oncol
Hlavní autoři: Ambinder, Alexander J., Norsworthy, Kelly, Hernandez, Daniela, Palau, Laura, Paun, Bogdan, Duffield, Amy, Chandraratna, Rosh, Sanders, Martin, Varadhan, Ravi, Jones, Richard J., Douglas Smith, B., Ghiaur, Gabriel
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2020
Témata:
Oncology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7645224/
https://ncbi.nlm.nih.gov/pubmed/33194741
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.587062
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky